Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 5/20 | 0.38 |
| ▸ | GAK | O14976 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.33 |
| ▸ | NEK2 | P51955 | 4/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29577707 | 1.00 | TTK (0.38) | TTKGAKLRRK2NEK2TP53 | |
| SCHEMBL24488200 | 0.95 | TTK (0.37) | TTKGAKLRRK2 | |
| SCHEMBL20331980 | 0.95 | TTK (0.37) | TTKGAKLRRK2 | |
| SCHEMBL21252449 | 0.88 | TTK (0.38) | TTKGAKLRRK2NEK2 | |
| SCHEMBL20331964 | 0.86 | PDE10A (0.36) | TTKNEK2TP53FGFR4 | |
| SCHEMBL29578107 | 0.86 | PDE10A (0.36) | TTKNEK2TP53FGFR4 | |
| SCHEMBL21240427 | 0.84 | SUV39H2 (0.36) | TTKGAKNEK2TP53FGFR4 | |
| SCHEMBL21240243 | 0.84 | TTK (0.38) | TTKNEK2TP53FGFR4 | |
| SCHEMBL29578389 | 0.84 | TTK (0.38) | TTKNEK2TP53FGFR4 | |
| SCHEMBL29578676 | 0.84 | SUV39H2 (0.36) | TTKGAKNEK2TP53FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11555036-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-01-17 | — | — | US | disclosed |
| EP-3524603-B1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2022-06-08 | — | — | EP | disclosed |
| US-10968220-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| US-10968220-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| US-20190270742-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2019-09-05 | — | — | US | disclosed |
| US-20190270742-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2019-09-05 | — | — | US | disclosed |
| EP-3524603-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2019-08-14 | — | — | EP | disclosed |
| EP-3524603-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2019-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270742-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | FGFR4, FGFR2, FGFR1 | TTK 3818/4885GAK 1714/4885LRRK2 743/4885 |
| US-11555036-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | FGFR4, FGFR2, FGFR1 | TTK 3818/4885GAK 1714/4885LRRK2 743/4885 |
| US-10968220-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | FGFR4, FGFR2, FGFR1 | TTK 3818/4885GAK 1714/4885LRRK2 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.